Evaluation of the corticosteroids therapy without biliary stenting in patients with obstructive jaundice due to autoimmune pancreatitis

Evaluation of the corticosteroids therapy without biliary stenting in patients with obstructive jaundice due to autoimmune pancreatitis - ECO-JAPAN study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034194

Enrollment

100

Registered

2018-12-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 autoimmune pancreatitis (AIP)

Interventions

without biliary stenting

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with suspect of type 1 autoimmune pancreatitis Agree to consent form Patients with ECOG performance status 0 or 1

Exclusion criteria

Exclusion criteria: 1) Liver dysfunction with viral hepatitis 2) Patients with acute cholangitis 3) Patients with ASA criteria 3, 4, or 5 4) Uncooperative patients 5) Refusal to consent form

Design outcomes

Primary

Measure	Time frame
The rate of improvement of liver tests after corticosteroid treatment in AIP patients.	—

Secondary

Measure	Time frame
1. Steroid-related adverse events (e.g. developed cholangitis or other infectious complications during steroid treatment) 2. Recurrent rate of obstructive jaundice during steroid treatment 3. Steroid-related complications 4. Comparing with control group about the above and medial expense	—

Countries

Japan

Contacts

Public ContactAkira Kurita

Kitano Hospital, Tazuke Kofukai Medical Research Institute Division of Gastroenterology and Hepatology, Digestive Disease Center

kuritaaki1976@gmail.com06-6131-2662

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026